Enfermedades infecciosas y microbiologia clinica最新文献

{"title":"Linfoma T pulmonar como causa infrecuente de lesiones nodulares pulmonares en paciente VIH","authors":"Antonio Rosales-Castillo , Antonio Bustos-Merlo , Carmen Hidalgo-Tenorio","doi":"10.1016/j.eimc.2025.03.002","DOIUrl":"10.1016/j.eimc.2025.03.002","url":null,"abstract":"","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 454-455"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En respuesta a: «Análisis de los costes asociados a la administración intramuscular versus oral de la terapia antirretroviral en el manejo de la infección por el virus de la inmunodeficiencia humana»","authors":"Luis Fernando Lopez Cortes , Laura Amanda Vallejo Aparicio , Cristina Jimenez Navarro , Lucía Ruiz Moran","doi":"10.1016/j.eimc.2025.04.007","DOIUrl":"10.1016/j.eimc.2025.04.007","url":null,"abstract":"","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 456-457"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","authors":"Raíssa de Fátima Silva-Afonso ,&nbsp;Guillermo Platas-Abenza ,&nbsp;María Guerrero-Soler ,&nbsp;Pilar Gallardo-Rodríguez ,&nbsp;Francisco Gil-Sánchez ,&nbsp;Gonzalo Pérez-Paz ,&nbsp;Lidia Cartagena-Llopis ,&nbsp;Marina Fuster-Pérez ,&nbsp;María Sánchez-Valero ,&nbsp;Ana Esclapez-Martínez ,&nbsp;Noemí Solís-Aniorte ,&nbsp;Yamilet Fernández-Martínez ,&nbsp;Elena Ronda-Pérez ,&nbsp;Isabel Escribano-Cañadas ,&nbsp;Juan Carlos Rodríguez-Díaz ,&nbsp;Esperanza Merino De Lucas ,&nbsp;Pablo Chico-Sánchez ,&nbsp;José Sánchez-Payá ,&nbsp;Paula Gras-Valentí","doi":"10.1016/j.eimc.2025.03.006","DOIUrl":"10.1016/j.eimc.2025.03.006","url":null,"abstract":"<div><h3>Introduction</h3><div>A public funded immunization program targeting influenza, COVID-19 and respiratory syncytial virus (RSV), was introduced in Spain for the 2023/2024 season. Effective immunization strategies depend on product coverage and effectiveness.</div></div><div><h3>Objectives</h3><div>Estimate of the impact of three severe acute respiratory infections (SARI) immunization strategies, during the 2023/2024 respiratory illness season in a Spanish health department.</div></div><div><h3>Methods</h3><div>We conducted an ecological study to compare cumulative hospitalization rates of SARI between the 2022/2023 and 2023/2024 seasons. Subsequently, a cross-sectional study was conducted to describe immunization coverage. Three observational test-negative case–control studies were carried out to evaluate the vaccine effectiveness (VE) against influenza and COVID-19 and the effectiveness of immunization with nirsevimab.</div></div><div><h3>Results</h3><div>During the 2023/2024 season 2952 patients were hospitalized due to SARI, representing hospitalization rates of 322.6/100,000 inhabitants (RR<!--> <!-->=<!--> <!-->0.78), indicating a 21.8% (CI: 14.8–28.1) overall effectiveness of the immunization strategies (EIS) against SARI. The global EIS for influenza was 26.7% (CI: 15.2–36.7), with 5.9% (CI: −10.1–19.5) for influenza A and 94.0% (CI: 86.4–97.4) for influenza B. For COVID-19, the EIS was 19.3% (CI: 7.2–29.3). The EIS for RSV was 52.5% (CI: 35.4–65.0) in children &lt;1 year-old. For the 2023/2024 season, influenza vaccination in those aged &gt;64 decreased 7.9%, while COVID-19 vaccination fell by 40.6% in individuals &gt;60 years. Nirsevimab reached high coverage of 94.78%. The aVE was 28.2% (CI: 4.7–45.9) for influenza and 29.2% (CI: 7.1–46.0) for COVID-19. The overall adjusted effectiveness of nirsevimab was 63.8% (CI: 9.6–85.5).</div></div><div><h3>Conclusion</h3><div>The observed EIS was likely due to RSV immunization in infants’ high coverage with good effectiveness and low influenza B circulation.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 435-443"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dirofilariasis subcutánea humana: presentación de un caso","authors":"Diana Nuevo-Silva ,&nbsp;Elena M. Garijo-Plano ,&nbsp;Macarena Pariente-Martín ,&nbsp;Juan J. Camarena-Miñana","doi":"10.1016/j.eimc.2024.12.013","DOIUrl":"10.1016/j.eimc.2024.12.013","url":null,"abstract":"","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 452-453"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Huellas de Uganda","authors":"Marina de la Puente Alonso ,&nbsp;Luis Ángel Zamarro Díaz ,&nbsp;Noelia Medrano Martínez ,&nbsp;Daniel Virseda González","doi":"10.1016/j.eimc.2024.12.012","DOIUrl":"10.1016/j.eimc.2024.12.012","url":null,"abstract":"","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 450-451"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simplified extraction method reduces the processing time for proteomic identification of nontuberculous mycobacteria","authors":"Ramiro López-Medrano ,&nbsp;Isabel Burgos-Asurmendi ,&nbsp;Octavio Rivero-Lezcano","doi":"10.1016/j.eimc.2025.03.001","DOIUrl":"10.1016/j.eimc.2025.03.001","url":null,"abstract":"<div><h3>Introduction</h3><div>The identification of nontuberculous mycobacteria (NTM) by proteomic procedures has improved in the last few years. Strains from different geographical locations differ in their proteomic patterns, limiting the applicability of general databases for accurate identifications.</div></div><div><h3>Methods</h3><div>We have optimized an alternative extraction protocol to Myco-Ex, and MBT, the protocols recommended by Bruker Daltonics, the manufacturer of MALDI Biotyper, a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) system. 120 clinical isolates, one environmental strain (<em>Mycobacterium canariasense</em>) and 7 quality controls were tested from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). All strains were also sent to the Laboratory of Mycobacteria belonging to the National Spanish Reference Center (Instituto de Salud Carlos III), that uses several molecular methods for mycobacterial identification. The proteomic extraction method includes a single extraction/inactivation formic acid step. 30 NTM strains were analyzed to certify the biosafety of the procedure, testing their viability after this procedure.</div></div><div><h3>Results</h3><div>The score ranges of the isolates were 1.61–2.16 (mean 1, 84) for the 88 isolates of the slow growing mycobacteria group (SGM) and 1.66–2.33 (mean 2.06) for the 40 isolates of the rapid growing mycobacteria group (RGM). Isolates exposed to formic acid were incubated for 8 weeks and growth was observed in neither the clinical isolates nor the controls.</div></div><div><h3>Conclusions</h3><div>We have developed a simpler and faster procedure for the proteomic identification of nontuberculous mycobacteria (MALDI-TOF) retaining significant scores without compromising biosafety.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 411-415"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with glucocorticoid dosing in treating patients with noncritical COVID-19 pneumonia: Insights from an artificial intelligence-based CT imaging analysis","authors":"Jie Wang ,&nbsp;Chang He ,&nbsp;Yu Shi ,&nbsp;Kunkai Su ,&nbsp;Zhihui Huang ,&nbsp;Songli Du ,&nbsp;Xukun Li ,&nbsp;Wei Wu ,&nbsp;Jifang Sheng","doi":"10.1016/j.eimc.2024.12.018","DOIUrl":"10.1016/j.eimc.2024.12.018","url":null,"abstract":"<div><h3>Objective</h3><div>Glucocorticoids are vital in treating COVID-19, but standard dosage for noncritical patients remain controversial. To determine the optimal glucocorticoid dosage for noncritical COVID-19 patients, we analyzed factors influencing dosage and developed a predictive model.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 273 noncritical COVID-19 pneumonia patients underwent pulmonary CT and treated with glucocorticoids in a tertiary hospital (12/2022–01/2023). Patients were divided into low and high glucocorticoid dosage groups based on a daily 40<!--> <!-->mg methylprednisolone or equivalent. Artificial intelligence (AI)-based deep learning was utilized to assess pulmonary CT images for accurate lesion area, which then analyzed through multivariable logistic regression to explore their correlation with glucocorticoid dosage. A predictive model was developed and validated for dosage prediction.</div></div><div><h3>Results</h3><div>The primary analysis included 243 patients, with 168 in the training set and 75 in the validation set. High-dose treatment was administered to 139 patients (82.7%) and low-dose to 29 patients (17.3%) in the training cohort. A predictive model incorporating normally inflated ratio, ground-glass opacity (GGO) ratio, and consolidation ratio accurately predicted selection of high- or low-dose, in both training (AUC<!--> <!-->=<!--> <!-->0.803) and validation cohorts (AUC<!--> <!-->=<!--> <!-->0.836), respectively. In 30 patients with post-CT adjusted dosages, the predicted dosages highly matched with the actual adjusted dosages.</div></div><div><h3>Conclusion</h3><div>Glucocorticoid dosages for noncritical COVID-19 pneumonia treatment are influenced by pulmonary CT features. Our predictive model can predict glucocorticoid dosage, however, should be validated by larger, prospective studies.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 402-410"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aspergilosis pulmonar invasiva grave producida por 2 especies diferentes de Aspergillus","authors":"Javier Romero López ,&nbsp;José María García de Lomas Guerrero ,&nbsp;Jesús Lancha Domínguez ,&nbsp;Francisco Javier Martínez Marcos","doi":"10.1016/j.eimc.2024.12.010","DOIUrl":"10.1016/j.eimc.2024.12.010","url":null,"abstract":"","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 448-449"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of follow-up blood cultures in Escherichia coli and Klebsiella pneumoniae bacteremia in geriatric patients","authors":"Sinan Çetin,&nbsp;Ferah Öğüt,&nbsp;Ahmet Melih Şahin,&nbsp;Meltem Arzu Yetkin","doi":"10.1016/j.eimc.2024.12.011","DOIUrl":"10.1016/j.eimc.2024.12.011","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to investigate the effect of obtaining follow-up blood cultures (FUBC) and persistent growth in FUBC on clinical outcomes in bacteremia cases caused by <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> in the geriatric age group.</div></div><div><h3>Methods</h3><div>Patients over 65 years of age with <em>E. coli</em> or <em>K. pneumoniae</em> bacteremia were included in the study. Patients were grouped as those who obtained FUBC and those who did not. Patients with FUBC were grouped as persistent bacteremia or negative FUBC. Demographic, clinical characteristics and outcomes were compared between these groups.</div></div><div><h3>Results</h3><div>A total of 142 patients were included. FUBC were obtained in 79 patients (55.6%) and persistent bacteremia was detected in 23 (29.1%). There were no significant differences in demographic data and clinical characteristics between patients with and without FUBC. There was no statistical difference in the outcomes between patients with of without FUBC. Patients with persistent bacteremia had a higher prevalence of diabetes mellitus, and the interval between index blood culture and FUBC was shorter (2.9 days <em>versus</em> 4.2 days). There was no difference between patients with persistent bacteremia and patients with no growth on FUBC in terms of length of hospital stay, need for intensive care unit, intubation, vasopressor therapy, and 14, 30, 90-day all-cause mortality.</div></div><div><h3>Conclusion</h3><div>In patients over 65 years of age with <em>E. coli</em> or <em>K. pneumoniae</em> bacteremia, neither obtaining FUBC nor persistent bacteremia on FUBC showed any difference in terms of outcomes such as mortality and need for admission to an intensive care unit.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 389-395"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of tuberculosis in Spain: Will the objectives of the End TB Strategy be achieved in Western European countries?","authors":"Teresa Rodrigo ,&nbsp;Joan P. Millet ,&nbsp;Mario Bravo ,&nbsp;Eva M. Tabernero ,&nbsp;Joan A. Caylà ,&nbsp;Tuberculosis Prevention and Control Programmes of the Autonomous Communities Working Group","doi":"10.1016/j.eimc.2025.02.004","DOIUrl":"10.1016/j.eimc.2025.02.004","url":null,"abstract":"<div><h3>Objectives</h3><div>End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC).</div></div><div><h3>Study design</h3><div>Retrospective longitudinal ecological study with forecasting.</div></div><div><h3>Methodology</h3><div>An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size.</div></div><div><h3>Results</h3><div>The mean annual % change in incidence rates of TB in the three most affected WEC during 2018–2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%.</div></div><div><h3>Conclusion</h3><div>With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 426-434"},"PeriodicalIF":2.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}